Immunovant (IMVT) Income Statement: Revenue & Earnings

Immunovant Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Immunovant, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	360.92	212.93	170.26	101.81	68.60	47.93
Selling, General & Administrative	77.24	57.28	48.02	54.23	39.51	18.15
Operating Expenses	438.15	270.21	208.28	156.03	108.12	66.08
Operating Income	-438.15	-270.21	-218.28	-156.03	-108.12	-66.08
Other Income/Expense
Interest Income	24.73	24.95	7.58	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00
Other Income/Expense	25.20	-1.01	-10.25	-0.78	-0.33	-0.41
Income
Income Before Tax	-412.95	-258.77	-210.95	-156.81	-107.79	-66.29
Income Tax Expense	0.89	0.57	0.01	-0.08	-0.36	0.10
Net Income	-413.84	-259.34	-210.96	-156.73	-107.43	-66.39
Net Income - Continuous Operations	-413.84	-259.34	-210.96	-156.73	0.00	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00	0.00
EBITDA	-437.78	-269.98	-217.21	-155.91	-108.05	-65.65
EBIT	-438.15	-270.21	-218.53	-156.03	-108.12	-65.67
Depreciation & Amortization	0.38	0.23	0.19	0.13	0.07	0.00
Earnings Per Share
Basic EPS	-3.00	-2.00	-2.00	-1.00	-1.00	-
Diluted EPS	-3.00	-2.00	-2.00	-1.00	-1.00	-2.00
Basic Shares Outstanding	151.57	138.10	123.08	109.68	87.76	43.20
Diluted Shares Outstanding	151.57	138.10	123.08	109.68	87.76	43.20